Paper II — 2016 October (Supplementary) (2010 Scheme) — Q6
3 min read
Paper II
2016 October (Supplementary) (2010 Scheme) · 40 marks · 120 min
Question
Artemisinin based combination therapy (ACT ) in malaria
Q63 marksShort Notes
Answer
Artemisinin-based combination therapy (ACT) is the WHO-recommended first-line treatment for uncomplicated P. falciparum malaria, including chloroquine-resistant/multidrug-resistant strains.
Rationale
Artemisinin derivatives (Artesunate, Artemether) produce rapid parasite clearance by generating free radicals that damage the parasite’s proteins/membranes (via cleavage of the endoperoxide bridge, catalysed by intraparasitic haem/iron), but have a short plasma half-life
Combining with a longer-acting partner drug (e.g., Lumefantrine, Sulfadoxine-pyrimethamine, Mefloquine) eliminates residual parasites and reduces the risk of recrudescence, while the rapid-acting artemisinin component reduces the parasite burden the partner drug has to handle — minimizing selection pressure for resistance to either drug
Examples
Artemether-Lumefantrine
Artesunate-Sulfadoxine-pyrimethamine
Artesunate-Mefloquine
Adverse effects
Generally well tolerated: GI upset, dizziness; rare neutropenia